NCT01300234 - Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB) | Biotech Hunter

Enrollment

512

Participants

Timeline

Start Date

March 30, 2011

Primary Completion Date

October 17, 2012

Study Completion Date

December 6, 2016

Conditions

Hepatitis B

Interventions

DRUG

Tenofovir disoproxil fumarate (TDF) tablets

white, almond-shaped, film-coated tablets containing 300mg of TDF

DRUG

Adefovir dipivoxil (ADV) tablets

white to off-white, round, biconvex tablets containing 10mg of ADV

Trial Locations (20)

100015

GSK Investigational Site, Beijing

100044

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

130021

GSK Investigational Site, Changchun

200001

GSK Investigational Site, Shanghai

200025

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

201508

GSK Investigational Site, Shanghai

210003

GSK Investigational Site, Nanjing

210029

GSK Investigational Site, Nanjing

250021

GSK Investigational Site, Jinan

310003

GSK Investigational Site, Hangzhou

350025

GSK Investigational Site, Fuzhou

400038

GSK Investigational Site, Chongqing

410008

GSK Investigational Site, Changsha

430030

GSK Investigational Site, Wuhan

510060

GSK Investigational Site, Guangzhou

510515

GSK Investigational Site, Guangzhou

510630

GSK Investigational Site, Guangzhou

610041

GSK Investigational Site, Chengdu